Assistant Professor of Medicine
TEL: (352) 273-9078
FAX: (352) 273-8889
Carsten Schmalfuss received his MD from the University of Essen, Germany in 1991. He completed a 2-year residency in Cardio-Thoracic Surgery and a year of Cardiology fellowship before coming to the United States in 1995. Here he completed his internship, residency and fellowship in Cardiology at Shands at the University of Florida, Gainesville, Florida.
Following this he became a full time Staff Cardiologist at the Malcom Randall VA Medical Center in Gainesville, Florida in 2002. At the same time he joined the Faculty of the Division of Cardiovascular Medicine at UF, where he is a Clinical Assistant Professor of Medicine. He was appointed Chief, Section of Cardiology at the Malcom Randall VA Medical Center in September 2011.
His field of interest is noninvasive Cardiac Imaging, particularly the use of CT and MRI. He is also involved in several pilot projects using Telemedicine in outpatient cardiac care of veterans. Dr. Schmalfuss is currently the Chair of the Research and Development Committee at the VA and a scientific member of the VA Central IRB.
He is board-certified in Internal Medicine and Cardiovascular Disease. He is a Fellow of the American College of Cardiology, the Society of Cardiac MR and the Society of Cardiac CT.
|MD||University of Essen, Germany||Medicine|
|Residency||University of Florida||Internal Medicine|
|Fellowship||University of Florida||Cardiovascular Medicine|
Dr. Schmalfuss is and has been involved in multiple pharmaceutical trials and several clinical trials evaluating CT and MRI of the cardiovascular system.
Dr. Schmalfuss’ clinical interests include noninvasive cardiovascular imaging and telemedicine.
Schmalfuss C. Tako-tsubo cardiomyopathy and cardiac magnetic resonance imaging. Clin Cardiol. 2011;34:145-6.
Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158:896-901.e3. [Schmalfuss CM]